EPRX
Eupraxia·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 0
Stock Price Surged Significantly
Ample Liquidity
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About EPRX
Eupraxia Pharmaceuticals Inc.
A clinical-stage biotechnology company focused on developing innovative drug delivery technologies.
201-2067 Cadboro Bay Road Victoria, British Columbia, Canada V8R 5G4
--
Eupraxia Pharmaceuticals Inc., was incorporated in British Columbia in May 2011. Eupraxia is a clinical-stage biotechnology company focused on developing local delivery, extended-release alternatives to existing drugs to create new products for the "first time" in molecular or drug categories, or "best-in-class" products for indications where efficacy has been established. Leveraging its proprietary and innovative DiffusihereTM delivery technology, Eupraxia's goal is to deliver the right dose of the drug in the right place and at the right time for indications with high unmet medical need. Each of Uprasha's product candidates is designed to improve patient benefit by providing longer-lasting activity than currently available treatments, combined with improved pharmacokinetics (" PK ") and related safety, and combined with precisely targeted topical delivery.
Company Financials
EPS
EPRX has released its 2025 Q3 earnings. EPS was reported at -0.19, versus the expected -0.19, meeting expectations. The chart below visualizes how EPRX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
